A61K36/81

Compositions in support of health and mental accuity
11596610 · 2023-03-07 · ·

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

Compositions in support of health and mental accuity
11596610 · 2023-03-07 · ·

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

HUMUS TREATMENT PROCESS WITH ACTIVE NEUROLOGICAL SUBSTANCES
20220323879 · 2022-10-13 ·

According to aspect of the present invention there is provided humus treatment process with active neurological substances, that is, the waste treatment process in the pharmaceutical industry. That uses raw materials from plants. The process involves treatment of fossil plants, Canabis sative, Mittragyna speciose, Datura metel and Magic mushrooms in order to allow residues in the plant to interact with the system. Nerves are depleted or less than the set value and allowing the production waste to be used in the processing of the fibers and agriculture industry.

COMPOSITIONS COMPRISING PLANT-DERIVED EXOSOME-LIKE NANOVESICLES OR EXOSOMES AND METHODS OF USE THEREOF

The present disclosure provides a composition comprising (a) exosome-like nanovesicles or exosomes and (b) a carrier, wherein the exosome-like nanovesicles or exosomes are extracted from Withania somnifera and methods of effecting a change in hair appearance, hair growth, hair pigmentation, hair follicle size or hair shaft size, comprising administering to the skin of a subject in need thereof an effective amount of such a composition.

COMPOSITIONS COMPRISING PLANT-DERIVED EXOSOME-LIKE NANOVESICLES OR EXOSOMES AND METHODS OF USE THEREOF

The present disclosure provides a composition comprising (a) exosome-like nanovesicles or exosomes and (b) a carrier, wherein the exosome-like nanovesicles or exosomes are extracted from Withania somnifera and methods of effecting a change in hair appearance, hair growth, hair pigmentation, hair follicle size or hair shaft size, comprising administering to the skin of a subject in need thereof an effective amount of such a composition.

COMPOSITIONS COMPRISING PLANT-DERIVED EXOSOME-LIKE NANOVESICLES OR EXOSOMES AND METHODS OF USE THEREOF

The present disclosure provides a composition comprising (a) exosome-like nanovesicles or exosomes and (b) a carrier, wherein the exosome-like nanovesicles or exosomes are extracted from Withania somnifera and methods of effecting a change in hair appearance, hair growth, hair pigmentation, hair follicle size or hair shaft size, comprising administering to the skin of a subject in need thereof an effective amount of such a composition.

Methods and compounds for treating effects of COVID-19 disease

Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

Methods and compounds for treating effects of COVID-19 disease

Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.

PSILOCYBIN AND PSILOCIN CONTAINING COMPOSITIONS AND METHODS OF USING AND MAKING THE SAME
20230115209 · 2023-04-13 ·

A composition is provided. The composition contains: (A) a psychoactive compound selected from the group consisting of psilocybin, psilocin, and combinations thereof; and (B) a supplement selected from the group consisting of an amino acid, a vitamin B6, piracetam, gamma aminobutyric acid (GABA), theobromine, caffeine, resveratrol, and combinations thereof. A method of producing the composition and an oral dosage containing the composition are also provided.

PSILOCYBIN AND PSILOCIN CONTAINING COMPOSITIONS AND METHODS OF USING AND MAKING THE SAME
20230115209 · 2023-04-13 ·

A composition is provided. The composition contains: (A) a psychoactive compound selected from the group consisting of psilocybin, psilocin, and combinations thereof; and (B) a supplement selected from the group consisting of an amino acid, a vitamin B6, piracetam, gamma aminobutyric acid (GABA), theobromine, caffeine, resveratrol, and combinations thereof. A method of producing the composition and an oral dosage containing the composition are also provided.